NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 14, 2024 and accepted by EDGAR at May 14, 2024, 20:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $1.4m | us-gaap:Revenues |
| Revenue | 6 months2023-10-01 to 2024-03-31 | $2.4m | us-gaap:Revenues |
| Cost of revenue | 3 months2024-01-01 to 2024-03-31 | $986.9k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-10-01 to 2024-03-31 | $1.7m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-01-01 to 2024-03-31 | $390.4k | us-gaap:GrossProfit |
| Gross profit | 6 months2023-10-01 to 2024-03-31 | $656.7k | us-gaap:GrossProfit |
| Research and development | 3 months2024-01-01 to 2024-03-31 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-10-01 to 2024-03-31 | $2.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-01-01 to 2024-03-31 | $2.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-10-01 to 2024-03-31 | $4.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-10-01 to 2024-03-31 | −$6.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$2.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-10-01 to 2024-03-31 | −$6.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-10-01 to 2024-03-31 | −$0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-10-01 to 2024-03-31 | −$0.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 25,910,478 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-10-01 to 2024-03-31 | 24,947,813 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-10-01 to 2024-03-31 | −$6.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-10-01 to 2024-03-31 | $68.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-31 | $2.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $4.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $5.4m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $1.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $1.5m | us-gaap:Liabilities |
| Short-term borrowings | At period end2024-03-31 | $121.9k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2024-03-31 | $3.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-24-042948. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.